The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis
Abstract Phosphoinositide-dependent phospholipase-C (PI-PLC) triggers the calcium signaling pathway which plays an important role in dense granule and microneme secretion and pathogenesis of Toxoplasma gondii (T. gondii). There are limited data about the effects of phospholipid analogues against T. gondii. The current study assessed the effect of edelfosine, as a phospholipid analogue, on GRA1 and MIC3 expressions using in vitro and in vivo models of acute toxoplasmosis. Infected Vero cells were treated by edelfosine in two subgroups: 24 h following the cell infection and treatment at the same time of cell infection. Animal study was performed on forty mice in four groups including non-infected, infected untreated, infected edelfosine-treated, and infected pyrimethamine-treated. Gene and protein expression analyses were done using quantitative real-time PCR and western blot, respectively. Edelfosine significantly reduced the GRA1 (P < 0.01) and MIC3 (P < 0.01) mRNA and protein expressions in 24 h following the cell infection and at the same time of cell infection groups. In vivo study showed that the edelfosine significantly reduced the GRA1 expression in eye, and MIC3 expression in brain and liver. Moreover, the edelfosine-treated infected mice had significant higher survival rate compared with uninfected mice. The reducing effect of edelfosine on GRA1 and MIC3 mRNA and protein levels 24 h following the cell infection was more than treatment at the same time of cell infection group. Moreover, the effect of edelfosine on GRA1 and MIC3 expression in animal tissues was variable. These data showed that the edelfosine may decrease the T. gondii excretory/secretory antigens through inhibition of PI-PLC..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:119 |
---|---|
Enthalten in: |
Parasitology research - 119(2020), 4 vom: 22. Jan., Seite 1371-1380 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Tanzifi, Asal [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Acute toxoplasmosis |
---|
Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2020 |
---|
doi: |
10.1007/s00436-020-06601-x |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC211740782X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC211740782X | ||
003 | DE-627 | ||
005 | 20230504133503.0 | ||
007 | tu | ||
008 | 230504s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00436-020-06601-x |2 doi | |
035 | |a (DE-627)OLC211740782X | ||
035 | |a (DE-He213)s00436-020-06601-x-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 570 |a 610 |a 630 |q VZ |
082 | 0 | 4 | |a 590 |a 610 |q VZ |
084 | |a 12 |2 ssgn | ||
100 | 1 | |a Tanzifi, Asal |e verfasserin |4 aut | |
245 | 1 | 0 | |a The effect of edelfosine on GRA1 and MIC3 expressions in acute toxoplasmosis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2020 | ||
520 | |a Abstract Phosphoinositide-dependent phospholipase-C (PI-PLC) triggers the calcium signaling pathway which plays an important role in dense granule and microneme secretion and pathogenesis of Toxoplasma gondii (T. gondii). There are limited data about the effects of phospholipid analogues against T. gondii. The current study assessed the effect of edelfosine, as a phospholipid analogue, on GRA1 and MIC3 expressions using in vitro and in vivo models of acute toxoplasmosis. Infected Vero cells were treated by edelfosine in two subgroups: 24 h following the cell infection and treatment at the same time of cell infection. Animal study was performed on forty mice in four groups including non-infected, infected untreated, infected edelfosine-treated, and infected pyrimethamine-treated. Gene and protein expression analyses were done using quantitative real-time PCR and western blot, respectively. Edelfosine significantly reduced the GRA1 (P < 0.01) and MIC3 (P < 0.01) mRNA and protein expressions in 24 h following the cell infection and at the same time of cell infection groups. In vivo study showed that the edelfosine significantly reduced the GRA1 expression in eye, and MIC3 expression in brain and liver. Moreover, the edelfosine-treated infected mice had significant higher survival rate compared with uninfected mice. The reducing effect of edelfosine on GRA1 and MIC3 mRNA and protein levels 24 h following the cell infection was more than treatment at the same time of cell infection group. Moreover, the effect of edelfosine on GRA1 and MIC3 expression in animal tissues was variable. These data showed that the edelfosine may decrease the T. gondii excretory/secretory antigens through inhibition of PI-PLC. | ||
650 | 4 | |a Toxoplasma gondii | |
650 | 4 | |a Acute toxoplasmosis | |
650 | 4 | |a Edelfosine | |
650 | 4 | |a GRA1 | |
650 | 4 | |a MIC3 | |
650 | 4 | |a Phosphoinositide-dependent phospholipase C | |
700 | 1 | |a Khoshi, Amirhosein |4 aut | |
700 | 1 | |a Emami, Saeed |4 aut | |
700 | 1 | |a Sarvi, Shahabeddin |4 aut | |
700 | 1 | |a Sharif, Mehdi |4 aut | |
700 | 1 | |a Montazeri, Mahbobeh |4 aut | |
700 | 1 | |a Moghbeli, Meysam |4 aut | |
700 | 1 | |a Daryani, Ahmad |0 (orcid)0000-0003-0228-0803 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Parasitology research |d Springer Berlin Heidelberg, 1987 |g 119(2020), 4 vom: 22. Jan., Seite 1371-1380 |w (DE-627)129863599 |w (DE-600)284966-5 |w (DE-576)015176576 |x 0932-0113 |7 nnns |
773 | 1 | 8 | |g volume:119 |g year:2020 |g number:4 |g day:22 |g month:01 |g pages:1371-1380 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00436-020-06601-x |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-VET | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_2018 | ||
912 | |a GBV_ILN_4277 | ||
951 | |a AR | ||
952 | |d 119 |j 2020 |e 4 |b 22 |c 01 |h 1371-1380 |